MA28694B1 - Traitement des infections bacteriennes - Google Patents

Traitement des infections bacteriennes

Info

Publication number
MA28694B1
MA28694B1 MA29579A MA29579A MA28694B1 MA 28694 B1 MA28694 B1 MA 28694B1 MA 29579 A MA29579 A MA 29579A MA 29579 A MA29579 A MA 29579A MA 28694 B1 MA28694 B1 MA 28694B1
Authority
MA
Morocco
Prior art keywords
treatment
bacterial infections
infections
bacterial
Prior art date
Application number
MA29579A
Other languages
English (en)
Inventor
James Peter Burnie
Ruth Christine Matthews
Tracey Carter
Original Assignee
Neutec Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutec Pharma Ltd filed Critical Neutec Pharma Ltd
Publication of MA28694B1 publication Critical patent/MA28694B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA29579A 2004-07-02 2006-12-29 Traitement des infections bacteriennes MA28694B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0414886.2A GB0414886D0 (en) 2004-07-02 2004-07-02 Treatment of bacterial infections

Publications (1)

Publication Number Publication Date
MA28694B1 true MA28694B1 (fr) 2007-06-01

Family

ID=32843487

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29579A MA28694B1 (fr) 2004-07-02 2006-12-29 Traitement des infections bacteriennes

Country Status (19)

Country Link
US (1) US7608265B2 (fr)
EP (1) EP1763539A1 (fr)
JP (1) JP2008505621A (fr)
KR (1) KR20070038539A (fr)
CN (1) CN101014621A (fr)
AU (1) AU2005258938A1 (fr)
BR (1) BRPI0512740A (fr)
CA (1) CA2569557A1 (fr)
EC (1) ECSP077220A (fr)
GB (1) GB0414886D0 (fr)
IL (1) IL180459A0 (fr)
MA (1) MA28694B1 (fr)
MX (1) MXPA06015081A (fr)
NO (1) NO20070567L (fr)
NZ (1) NZ552110A (fr)
RU (1) RU2377251C2 (fr)
TN (1) TNSN06453A1 (fr)
WO (1) WO2006003426A1 (fr)
ZA (1) ZA200610279B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10364298B2 (en) 2011-11-18 2019-07-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
EP2806882B1 (fr) 2012-01-23 2018-11-14 Santalis Pharmaceuticals Inc. Huile de bois de santal et ses utilisations afférentes aux infections à clostridium
WO2014085821A2 (fr) * 2012-11-30 2014-06-05 The Regents Of The University Of California Anticorps entièrement humains et fragments reconnaissant la protéine c-met humaine
CN103044527B (zh) * 2012-12-21 2014-08-06 南昌大学 庆大霉素的抗原模拟表位及其应用
US11291693B2 (en) 2015-06-25 2022-04-05 Synlogic Operating Company, Inc. Bacteria engineered to treat metabolic diseases
KR102487338B1 (ko) * 2020-12-18 2023-01-12 한국지질자원연구원 점토광물 복합체를 포함하는 cdi 치료용 약학적 조성물 및 그 제조방법
US20250230260A1 (en) * 2022-04-15 2025-07-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Cdrs for glycosylated acat1

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
CA2006878A1 (fr) 1988-12-29 1990-06-29 John D. Rodwell Systemes de caracterisation moleculaire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
DE69619894T2 (de) * 1995-06-30 2002-11-14 American Cyanamid Co., Madison Stabile Makrolide und Makrolide Imptstoff-Zusammensetzungen
GB9621295D0 (en) 1995-12-07 1996-11-27 Cambridge Antibody Tech Specific binding members,materials and methods
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
EP1024826B1 (fr) 1997-10-20 2005-03-16 Acambis, Inc. Immunisation passive contre la maladie de clostridium difficile
DE69901569T2 (de) 1998-08-28 2002-12-19 Genentech, Inc. Humane antikörper gegen faktor ix/ixa
AU7676300A (en) 1999-10-12 2001-04-23 Cambridge Antibody Technology Limited Human anti-adipocyte monoclonal antibodies and their use
AU770115B2 (en) 1999-12-13 2004-02-12 Cambridge Antibody Technology Limited Brain specific binding members
AU2001281824A1 (en) * 2000-06-15 2001-12-24 Patrizia Castellani Methods for quantitative determination of b-fibronectin in biological fluids and tissues
DE60124313T2 (de) 2001-01-15 2007-05-31 Keryos S.P.A. Dns-vakzine von hypervariablen vh-cdr3 idiotypischen determinanten
US20030054009A1 (en) 2001-02-09 2003-03-20 Windle Henry J. Clostridium difficile vaccine
EP1461428B1 (fr) * 2001-12-03 2012-03-21 Alexion Pharmaceuticals, Inc. Méthode de production d'anticorps hybrides
GB0130267D0 (en) * 2001-12-19 2002-02-06 Neutec Pharma Plc Focussed antibody technology
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies

Also Published As

Publication number Publication date
EP1763539A1 (fr) 2007-03-21
MXPA06015081A (es) 2007-07-20
TNSN06453A1 (en) 2008-02-22
RU2377251C2 (ru) 2009-12-27
KR20070038539A (ko) 2007-04-10
IL180459A0 (en) 2007-06-03
AU2005258938A1 (en) 2006-01-12
RU2007104033A (ru) 2008-08-10
GB0414886D0 (en) 2004-08-04
ZA200610279B (en) 2008-08-27
JP2008505621A (ja) 2008-02-28
CN101014621A (zh) 2007-08-08
CA2569557A1 (fr) 2006-01-12
WO2006003426A1 (fr) 2006-01-12
NZ552110A (en) 2010-11-26
ECSP077220A (es) 2007-03-29
US7608265B2 (en) 2009-10-27
NO20070567L (no) 2007-01-30
BRPI0512740A (pt) 2008-04-08
US20080038266A1 (en) 2008-02-14

Similar Documents

Publication Publication Date Title
EP1812068A4 (fr) Méthodes de prévention et de traitement des infections à rsv et des états pathologiques associés
EP1968582A4 (fr) Traitement du lymphome t cutane
EP2081593A4 (fr) Vaccins bacteriens vivants pour la prophylaxie ou le traitement d'une infection virale
EP1755584A4 (fr) Traitement de la myopie
EP1744751A4 (fr) Traitement des synucleinopathies
EP1765288A4 (fr) Methodes de traitement d'infections endobronchiques
EP1830876A4 (fr) Traitement de metastases cutanees
EP1898930A4 (fr) Traitement d'etats inflammatoires
EP1982660A4 (fr) Endoscope de traitement
EP3117832C0 (fr) Traitement d'infections microbiennes
EP2273989A4 (fr) Polythérapie pour le traitement des infections bactériennes
PL1951272T3 (pl) Zastosowanie lactobacillus do leczenia infekcji wirusowych
EP1957413A4 (fr) Traitement des eaux d'egout
CR9878A (es) Tratamiento y profilaxis de microangiopatias
IL187111A0 (en) Use of tfpi to treat severe bacterial infections
ZA200704392B (en) Antibiotic combinations for providing total solution to the treatment of infections
EP1677816A4 (fr) Methode de traitement
FR2943537B1 (fr) Traitement des nevrites vestibulaires par l'acetyl-l-leucine
EP2217573A4 (fr) Traitement et prévention d'infections virales
EP1965827A4 (fr) Traitement d'etats lies a la demyelination
FI20095600L (fi) Koostumus ihosairauksien hoitoa varten
FR2876047B1 (fr) Traitement de polluants par phytolixiviation
GB0513096D0 (en) Treatment of microbial infections
ZA200802934B (en) Use of lactobacillus for treatment of virus infections
EP1881760A4 (fr) Traitement antimicrobien pour infections bactériennes